Regulatory Approval - Novo Nordisk's Wegovy received FDA approval to treat a serious liver disease [1] Pharmaceutical Industry - Wegovy is described as a blockbuster weight-loss drug [1]

Market Dynamics & Drug Approvals - Novo Nordisk's weight loss drug VGOI receives FDA approval for treating a serious metabolic liver disease [1] - Novo Nordisk to sell Ozmpic directly to consumers through its Novocare platform at $4.99 per month for out-of-pocket payers [2] - Ozmpic and WGOI share the same active ingredient, but Ozmpic is approved for diabetes, while WGOI is for weight loss [3] Competitive Landscape & Pricing Strategies - Novo Nordisk aims to combat compounders selling knockoff versions of semaglutide, which impacted the company's full-year sales forecast [5] - Legitimate versions of weight loss drugs from Eli Lilly and Novo Nordisk are priced around $500, competing with compounded versions available for $200-$300 per month [6] - Eli Lilly increased the price of Mounjaro in the UK to equalize prices with the US and other countries [8] Future Outlook & Market Evolution - The market is evolving with oral versions and new companies entering, but the oral drug data from Lily disappointed investors [10][11] - Medicare will soon negotiate the price of Ozmpic, potentially affecting WGOI and spilling into the commercial market, which could lower prices [13] - Manufacturing costs pose a significant barrier to entry for new competitors against established players like Novo Nordisk [14]

Core Viewpoint - Novo Nordisk's stock is experiencing a rebound after FDA approval for its weight-loss drug Wegovy to treat liver disease, following a significant drop in its stock price earlier this month [1]. Group 1: Stock Performance - The stock is currently trading at $54.10, reflecting a 3.1% increase [1]. - The company faced a 21.8% decline on July 29, marking its worst drop on record, and is down 39% in 2025 [2]. - The $50 level is now acting as a support floor for the stock [2]. Group 2: Market Sentiment - Short-term traders are showing a put-bias, indicated by a Schaeffer's put/call open interest ratio (SOIR) of 1.10, which is in the 99th percentile of the past year [2]. - There is potential for upgrades, as 14 out of 20 brokerages currently have a "hold" or worse recommendation [3]. - The stock has historically outperformed volatility expectations, with a Schaeffer's Volatility Scorecard (SVS) of 87 out of 100 [3].

21:15 中概股盘前表现活跃，迅雷大涨超23%，爱奇艺涨17%，斗鱼涨超9%。 21:30 美股开盘丨美股三大指数小幅低开中概股普涨 道指跌0.14%，标普500指数跌0.09%，纳指跌0.06%。中概股普涨，纳斯达克中国金龙指数涨1.2%，迅 雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%，其新药获批后降低Ozempic价格。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 道琼斯工业指数 | 44883.39 | -62.73 | -0.14% | | 纳斯达克指数 | 21609.23 c | -13.75 | -0.06% | | 标普500 | 6443.85 | -5.95 | -0.09% | 16:34 联合健康美股盘前涨超3%。 （文章来源：第一财经） 21:06 诺和诺德美股盘前涨超5%，美国FDA批准将减肥药Wegovy用于肝病治疗。 ...

每经AI快讯，8月18日，美股三大指数开盘集体下跌，道琼斯指数跌0.14%，标普500指数跌0.11%，纳 斯达克综合指数跌0.05%。中概股普涨，迅雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%。 ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. https://t.co/4oygIL7lub ...

Core Insights - Novo Nordisk has reduced the cash price of its diabetes treatment Ozempic to less than half of its monthly list price in response to political pressure for lower drug prices in the U.S. [1] Pricing and Accessibility - Patients can now pay $499 in cash per month for Ozempic, available in three dose sizes, through various platforms including the drug's official website and Novo Nordisk's patient assistance program [2] - GoodRx will also offer Ozempic and its weight loss counterpart Wegovy at the same price of $499 per month, accessible at over 70,000 pharmacies nationwide, enhancing affordability for patients [3] - This cash-pay offering aims to increase access for eligible Type 2 diabetes patients who lack insurance coverage for the weekly injection [3]

CONTACT: CONTACT US HERE: DEADLINE: September 30, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form-3/? id=161651&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NVO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. ...

Group 1 - Ukrainian President Zelensky is set to meet with US President Trump on August 18, 2023, to discuss the ongoing Russia-Ukraine conflict, followed by a multilateral meeting with European leaders [1] - Major US stock indices, including Dow Jones, S&P 500, and Nasdaq, experienced slight declines, with Dow futures down 0.15%, S&P 500 futures down 0.16%, and Nasdaq futures down 0.16% [2] - Semiconductor stocks in the US saw a collective decline, with Intel down 1.18%, AMD down 0.77%, and Nvidia down 0.38% [3] Group 2 - The Federal Reserve has relaxed its regulatory stance on banks' cryptocurrency activities, leading to a drop in cryptocurrency exchange stocks, with Coinbase down 1.67% and Circle down 1.07% [5] - Novo Nordisk's weight loss drug Wegovy received FDA approval for treating metabolic fatty liver disease, resulting in a 4.02% increase in the company's stock [6] - OpenAI employees plan to sell approximately $6 billion worth of stock at a valuation of $500 billion to a group of investors including Thrive Capital and SoftBank [7] Group 3 - Tesla is offering rental discounts of about 40% in the UK due to declining sales, with July sales dropping to 987 units, a year-on-year decrease of approximately 60% [8] - NIO announced plans to enter the markets of Singapore, Uzbekistan, and Costa Rica between 2025 and 2026, with a collaboration in Singapore to launch a right-hand drive model [9]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who acquired the company's securities between May 7, 2025, and July 28, 2025, alleging misrepresentations regarding the growth potential of its diabetes/obesity drug, GLP-1 [1][3]. Group 1 - The lawsuit claims that the defendants made misrepresentations about Novo's growth potential related to its diabetes/obesity drug, GLP-1 [3]. - The deadline for potential lead plaintiffs to file papers is September 30, 2025 [4]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].